Literature DB >> 11900277

Effect of treating streptozotocin-induced diabetic rats with sorbinil, myo-inositol or aminoguanidine on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve.

Lawrence J Coppey1, Jill S Gellett, Eric P Davidson, Joyce A Dunlap, Mark A Yorek.   

Abstract

Previously we have demonstrated that diabetes causes impairment in vascular function of epineurial vessels, which precedes the slowing of motor nerve conduction velocity. Treatment of diabetic rats with aldose reductase inhibitors, aminoguanidine or myo-inositol supplementation have been shown to improve motor nerve conduction velocity and/or decreased endoneurial blood flow. However, the effect these treatments have on vascular reactivity of epineurial vessels of the sciatic nerve is unknown. In these studies we examined the effect of treating streptozotocin-induced rats with sorbinil, aminoguanidine or myo-inositol on motor nerve conduction velocity, endoneurial blood flow and endothelium-dependent vascular relaxation of arterioles that provide circulation to the region of the sciatic nerve. Treating diabetic rats with sorbinil, aminoguanidine or myo-inositol improved the reduction of endoneurial blood flow and motor nerve conduction velocity. However, only sorbinil treatment significantly improved the diabetes-induced impairment of acetylcholine-mediated vasodilation of epineurial vessels of the sciatic nerve. All three treatments were efficacious in preventing the appropriate metabolic derangements associated with either activation of the polyol pathway or increased nonenzymatic glycation. In addition, sorbinil was shown to prevent the diabetes-induced decrease in lens glutathione level. However, other markers of oxidative stress were not vividly improved by these treatments. These studies suggest that sorbinil treatment may be more effective in preventing neural dysfunction in diabetes than either aminoguanidine or myo-inositol.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11900277      PMCID: PMC2478566          DOI: 10.1080/15604280212525

Source DB:  PubMed          Journal:  Int J Exp Diabetes Res        ISSN: 1560-4284


  20 in total

1.  Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications.

Authors:  Eric P Davidson; Lawrence J Coppey; Amey Holmes; Brian Dake; Mark A Yorek
Journal:  Eur J Pharmacol       Date:  2011-07-28       Impact factor: 4.432

2.  Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats.

Authors:  Christine L Oltman; Eric P Davidson; Lawrence J Coppey; Travis L Kleinschmidt; Brian Dake; Mark A Yorek
Journal:  Eur J Pharmacol       Date:  2010-10-30       Impact factor: 4.432

3.  Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes.

Authors:  N Karachalias; R Babaei-Jadidi; N Rabbani; P J Thornalley
Journal:  Diabetologia       Date:  2010-04-06       Impact factor: 10.122

4.  Carbonylation of myosin heavy chains in rat heart during diabetes.

Authors:  Chun-Hong Shao; George J Rozanski; Ryoji Nagai; Frank E Stockdale; Kaushik P Patel; Mu Wang; Jaipaul Singh; William G Mayhan; Keshore R Bidasee
Journal:  Biochem Pharmacol       Date:  2010-03-30       Impact factor: 5.858

5.  Chronic oral pelargonidin alleviates streptozotocin-induced diabetic neuropathic hyperalgesia in rat: involvement of oxidative stress.

Authors:  Mohammadali Mirshekar; Mehrdad Roghani; Mohsen Khalili; Tourandokht Baluchnejadmojarad; Saiedeh Arab Moazzen
Journal:  Iran Biomed J       Date:  2010 Jan-Apr

6.  Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats.

Authors:  Eric P Davidson; Lawrence J Coppey; Amey Holmes; Mark A Yorek
Journal:  Eur J Pharmacol       Date:  2011-12-14       Impact factor: 4.432

Review 7.  Future treatments for diabetic neuropathy: clues from experimental neuropathy.

Authors:  Nigel A Calcutt
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 8.  Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities.

Authors:  William I Sivitz; Mark A Yorek
Journal:  Antioxid Redox Signal       Date:  2010-04       Impact factor: 8.401

Review 9.  Vascular Impairment of Epineurial Arterioles of the Sciatic Nerve: Implications for Diabetic Peripheral Neuropathy.

Authors:  Mark A Yorek
Journal:  Rev Diabet Stud       Date:  2015-08-10

Review 10.  Update on the pathogenesis of diabetic neuropathy.

Authors:  Irina G Obrosova
Journal:  Curr Diab Rep       Date:  2003-12       Impact factor: 5.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.